FORMYCON WKN: A1EWVY ISIN: DE000A1EWVY8 Forum: Aktien Thema: Hauptdiskussion

Nachreichung zum Trump Thema: "One way Trump aimed to help lower prices was through free market competition and promoting biosimilars. By signing a law in 2018 that gave the FTC greater access to deals involving biosimilars, Trump signaled that expensive biologics like AbbVie’s top-selling Humira could face more competition,, and since the law passed, the approval of biosimilars overall has risen steadily.For the pharma industry, the biosimilars act has both helped and hurt the bottom line. Some companies like AbbVie have lost control of the market for drugs like Humira while others have gained traction due to their biosimilar pipelines. Many companies, like Amgen, Pfizer and Roche, are in both camps by selling both branded biologics and biosimilars. " https://www.biopharmadive.com/news/trump-white-house-biosimilar-FTC-law/539331/

Das klingt aber „kriminell gut“ für uns ;)